For the estimated 40–60% of heart attack patients who arrive at the cath lab with blockages in multiple coronary arteries, a longstanding clinical debate has real consequences: should cardiologists fix only the artery that caused the acute event, or address other diseased vessels at the same sitting — or later? The answer shapes recovery trajectories, rehospitalization rates, and potentially survival, making this one of the more consequential procedural decisions in interventional cardiology.
This New England Journal of Medicine trial directly compared immediate versus deferred percutaneous coronary intervention (PCI) of nonculprit lesions — coronary blockages not responsible for the index myocardial infarction — in patients presenting with acute MI and multivessel disease. The study enrolled patients across multiple centers and randomized them to have secondary lesions treated either during the same procedure as the primary culprit-vessel PCI or at a staged, planned intervention shortly thereafter. The primary endpoints centered on major adverse cardiovascular events including repeat MI, unplanned revascularization, and cardiovascular mortality over a defined follow-up window.
This trial enters a crowded but still unsettled evidence base. Earlier landmark trials such as COMPLETE and DANAMI-3–PRIMULTI established that complete revascularization is generally superior to culprit-only PCI, reducing ischemia-driven events. What has remained genuinely contested is the optimal timing of that secondary intervention. Physiology-guided approaches using fractional flow reserve to select which lesions truly warrant treatment have added another layer of nuance. The practical implications for adult patients with atherosclerotic disease are substantial: immediate complete revascularization reduces hospital visits but may expose hemodynamically unstable patients to prolonged procedure risk, while deferral allows for clinical stabilization. This study is best interpreted as incrementally clarifying the timing question within an already pro-complete-revascularization consensus, rather than overturning established practice. Confirmatory evidence from adequately powered trials remains essential before uniform protocols shift.